The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

USPTO Issues Horizon Pharma an Additional Notice of Allowance

07-Sep-2015 | Source : Horizon Pharma | Visits : 6516
DUBLIN, IRELAND - Horizon Pharma plc announced in a press release that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for US patent application number 14/705,606 (US publication number 2015-0231262), entitled "Diclofenac Topical Formulation" that covers Horizon's US approved product PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%).

"We continue to look at broader intellectual property prosecution strategies to strengthen and grow our patent estate across our portfolio," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "PENNSAID 2% is a great example of how our prosecution strategy and execution has worked as we have nearly doubled the number of allowed patents since acquiring the rights in fourth quarter 2014."

This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a US patent after administrative processes are completed. The US patent scheduled to issue from this application will expire October 17, 2027. After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

PENNSAID (diclofenac sodium topical solution) 2% w/w is a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain of osteoarthritis (OA) of the knee(s). PENNSAID 2% contains diclofenac sodium, an NSAID, and also includes dimethyl sulfoxide (DMSO), a powerful penetrating agent that helps ensure that diclofenac sodium is absorbed through the skin to the site of inflammation and pain. PENNSAID 2% is an alternative to oral NSAID treatment, reducing systemic exposure to a fraction of that provided by the oral NSAID diclofenac. 

Related Articles